Clinical trials: Dementia, Mild
Alzheimer Disease, Dementia, Mild
Event-Related Potential (ERP) Components in Clinical Diagnosis
In this study, the investigators will use a novel electroencephalogram (EEG) system that participants will wear during a single in-person research session to investigate whether ERPs are now ready for validation as a tool…
- Conditions
- Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
- Trial name
- NCT05673759
- Testing
- Electroencephalogram (EEG) system, Standard Neuropsychological Testing, Additional neuropsychological tests
- Where
- United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Boston University
Healthy Older Adults, Memory Complaints
A Computer-based Memory Strategy Training Program for Older Adults
A computer-based cognitive rehabilitation program based on daily tasks utilising the semantic or perceptual encoding strategies called Enhancing Memory in Daily Life (E-MinD Life) has been developed for Chinese people.
- Conditions
- Healthy Older Adults, Memory Complaints, Mild Cognitive Impairment (MCI)
- Trial name
- NCT07039708
- Testing
- E-MinD Life Semantic, Cognitive stimulation
- Where
- Hong Kong
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Alzheimer Disease, Early Onset, MCI
The Interactive Physical and Cognitive Exercise System
This study is intended to clarify the benefits to brain health and thinking processes that result from different forms of exercise.
- Conditions
- Alzheimer Disease, Early Onset, MCI, Aging, Mild Cognitive Impairment
- Trial name
- iPACES™ (NCT03069391)
- Testing
- physical exercise alone (PES) first, cognitive exercise alone (iCE) first, interactive Physical and Cognitive Exercise (iPACES™)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Union College, New York
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
The proposed study is designed to evaluate the performance of the ALTOIDA™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Disorders, Cognitive Impairment
- Trial name
- AltoidaML (NCT02843529)
- Testing
- Altoida: neuropsychological, MRI, EEG and CSF biomarkers
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Altoida
Dementia
The Effect of Digital Reminiscence Therapy on People With Mild and Moderate Dementia
In the post-epidemic era, it is necessary to develop support programs for families with dementia in empirical care. The reminiscence therapy was adopted by patients with mild and moderate dementia those intervention have had good…
- Trial name
- NCT05341271
- Testing
- Experimental: digital reminiscence group (DRG), Experimental: general reminiscence group (GRG)
- Where
- Taiwan
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- National Taipei University of Nursing and Health Sciences
Alzheimer Disease, Healthy Aging
Developing an Artificial Intelligence System to Detect Cognitive Impairment
Alzheimer's disease dementia (AD) is a debilitating and prevalent neurodegenerative disease in older adults globally. Cognitive impairment, a hallmark of AD, is assessed through verbal tests that require high specialization, and…
- Conditions
- Alzheimer Disease, Healthy Aging, Mild Cognitive Impairment
- Trial name
- NCT05794451
- Where
- Israel
- Volunteers
- 3,413 people, healthy volunteers welcome
- Sponsor
- University of Haifa
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
Remote Digital Assessments for Cognitive Disorders
Memory and thinking problems in older adults, including mild cognitive impairment (MCI) and Alzheimer's disease (AD), can be difficult to assess promptly because evaluation often depends on in-person specialist visits.
- Trial name
- MonitorCog-AI (NCT07883746)
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Alzheimer's Disease, Mild Cognitive Impairment
A Composite MR Neuroimaging Marker for Alzheimer's Disease
The purpose of this study is to use a functional MRI (fMRI) index to compare the brain activity of healthy volunteers to that of people with mild cognitive impairment (MCI) and Alzheimer's disease.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Frontotemporal Dementia
- Trial name
- NCT01615666
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Parkinson Disease, Alzheimer Disease
Autoimmune Features of Neurodegenerative Disorders
This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD).
- Conditions
- Parkinson Disease, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT04239079
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Columbia University
Obstructive Sleep Apnea of Adult, Mild Cognitive Impairment
The Relationship Between Obstructive Sleep Apnea and Alzheimer's Disease: Evidence and Effectiveness
The research plan to enroll 15 simple snoring patients (apnea/hypopnea <5, control group), 30 severe OSA patients (apnea/hypopnea >30, treatment group), and 15 mild cognitive impairment patients (comparative group).
- Trial name
- OSA (NCT05433883)
- Testing
- sleep surgery
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Cognitive Impairment, Dementia
COcoa Supplement and Multivitamin Outcomes Study for the Mind
The parent trial (COcoa Supplement and Multivitamin Outcomes Study, COSMOS; NCT02422745) is a randomized clinical trial of cocoa extract supplement (containing a total of 500 mg/d flavanols, including 80 mg.
- Conditions
- Cognitive Impairment, Dementia, Aging
- Trial name
- COSMOS-Mind (NCT03035201)
- Where
- United States
- Volunteers
- 2,262 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Mild Cognitive Impairment, Alzheimer's Disease
Use of Wearables for Identifying Factors Associated With Mild Cognitive Impairment and Early-Stage Alzheimer's Disease
Cognitive decline affects millions of older adults worldwide and has a profound impact on individuals, families, and healthcare systems.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease Dementia
- Trial name
- NCT07391436
- Where
- Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Getúlio Vargas University Hospital
Aging, Mild Cognitive Impairment
China Longitudinal Aging and Cognitive Impairment Study
This is a multi-center longitudinal study that consists of five cohorts: cognitive normal aging (CN), Subjective cognitive impairment (SCI), mild cognitive impairment (MCI), Alzheimer's disease (AD) and vascular cognitive…
- Conditions
- Aging, Mild Cognitive Impairment, Alzheimer Disease, Neurodegeneration
- Trial name
- CLACIS (NCT05468905)
- Testing
- None of intervention
- Where
- 2 sites in China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Dementia, Alzheimer Dementia (AD)
Fuzhou Aging Brain Health Initiative
The goal of this observational study is to learn about the pathophysiological characterization and evolutionary patterns of Alzheimer's disease (AD) in older adults in Fujian Province, China.
- Conditions
- Dementia, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- FAITH (NCT07891429)
- Testing
- Fluids biomarker and neuroimaging of AD diagnosis
- Where
- 4 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Cognitive Impairment
Ascending Dose Study of CT1812 in Healthy Volunteers
This is a double-blind, placebo controlled, ascending dose, multi-cohort trial. The study will be conducted in two phases: a single ascending dose (SAD) phase "Part A", followed by a multiple ascending dose (MAD) phase "Part B".
- Trial name
- NCT02570997
- Testing
- CT1812
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Cognition Therapeutics
Alzheimer Disease
Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects
This is an investigator-initiated clinical (IIT)study.The main purpose of this study was to evaluate the diagnostic efficacy of XTR006 PET qualitative reading and quantitative analysis in detecting mild cognitive…
- Trial name
- NCT06151808
- Testing
- XTR006
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer Disease, Healthy Aging
Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment
The purpose of this study is to measure the amount of amyloid in the brain. Amyloid is a protein found in the brain of patients with Alzheimer's disease and can be detected using a Positron Emission Tomography (PET) scan.
- Trial name
- NCT04505735
- Testing
- 11C-PiB
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Mild Cognitive Impairment, Dementia
Implications for Management of PET Amyloid Classification Technology
The main purpose of this study is to explore the impact of an amyloid positron emission tomography and computed tomography (PET/CT) scan on physician diagnosis and management, including drug management and care practices, for…
- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer's Disease
- Trial name
- IMPACT (NCT02778971)
- Testing
- [18F]Flutemetamol
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Utah
Alzheimer Disease
Memory Functions in Mild Alzheimer's Disease
The overall objective of this project is to examine the effects of non-invasive brain stimulation on episodic memory performance
- Trial name
- MemStim-lab (NCT04785053)
- Testing
- transcranial alternating current stimulation (tACS)
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Hebrew SeniorLife
Alzheimer Disease, Dementia
BarcelonaBeta Dementia Prevention Research Clinic: a Study on Risk Factors Disclosure
Alzheimer's disease (AD) is the leading cause of dementia and its prevalence is estimated to exceed 100 million affects by 2050, becoming the main public health problem worldwide.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Subjective Cognitive Decline
- Trial name
- NCT03847038
- Testing
- Preventive strategies advice and dementia risk estimate disclosure
- Where
- Spain
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation